|
See related Xarelto film-coated tab information |
|
|
|
Manufacturer |
Bayer HealthCare Pharma |
|
Distributor |
DKSH |
|
Contents |
Rivaroxaban |
|
Indications |
Prevention of VTE in patients undergoing major orthopaedic surgery of the lower limbs.
Click to view Xarelto detailed prescribing infomation |
|
Dosage |
1 tab once daily for 5 wk (major hip surgery) or 2 wk (major knee surgery). Initial dose to be taken 6-10 hr after surgery provided that hemostasis has been established.
Click to view Xarelto detailed prescribing infomation |
|
Overdosage |
View Xarelto overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy leading to a clinically relevant bleeding risk. Pregnancy & lactation.
Click to view Xarelto detailed prescribing infomation |
|
Special Precautions |
Moderate to severe renal impairment, congenital or acquired bleeding disorders; uncontrolled severe arterial HTN; active & recent GI ulcerations; vascular retinopathy; recent intracranial or intracerebral hemorrhage, intraspinal or intracerebral vascular abnormalities; recent brain, spinal or ophthalmological surgery; hip fracture surgery; spinal/epidural anesth or puncture. Women of childbearing potential. Concomitant NSAIDs, platelet aggregation inhibitors, other antithrombotics.
Click to view Xarelto detailed prescribing infomation |
|
Adverse Drug Reactions |
Increased γ-glutamyl transferase & transaminases (ALT & AST); anaemia; nausea; postprocedural haemorrhage.
View ADR Monitoring Form |
|
Drug Interactions |
Azole antimycotics, HIV-PIs, clopidogrel.
View more drug interactions with Xarelto |
|
Storage |
View Xarelto storage conditions for details to ensure optimal shelf-life. |
|
Mechanism of Action |
View Xarelto mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
